Contact Us

EpicentRx’s “PRETECT” program is led by a first-in-class small molecule, nibrozetone (RRx-001), in Phase 3 and Phase 2b cancer clinical trials, as well as a Phase 1 clinical trial in endometriosis and pre-Phase 1 studies in neurodegenerative diseases like Parkinson’s, ALS/MND and Gulf War Illness (GWI). “PRETECT” is a hybrid word of pretreatment and protection since RRx-001 administration often occurs prior to the start of other therapies.

TONY REID, M.D. Ph.D.

Chief Executive Officer & Chief Scientific Office

BIO

FRANCK BRINKHAUS, Ph.D.

Chief Financial Officer

BIO

BRYAN ORONSKY, M.D. Ph.D.

Chief Medical Officer

BIO

CHRIS LARSON,
M.D. Ph.D.
Vice President of Viral Therapy

BIO

MEAGHAN STIRN,
M.B.A
Controller & VP of Special Projects

BIO

SCOTT CAROEN
Senior Director of Operations & Corporate Development

BIO

Rajan Kumar
ESQ
Chief Executive Officer & Chief Scientific Office

BIO

pulsing dot

Send us a message

ADDRESS
11099 North Torrey Pines Road
Suite 160, La Jolla, CA 92037
CALL US
Phone: 858.947.6635
Fax: 858.724.3080
EMAIL US